BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 2013;24:66-72. [PMID: 23147412 DOI: 10.1097/CAD.0b013e3283584f75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Ruan L, Wang L, Wang X, He M, Yao X. SIRT1 contributes to neuroendocrine differentiation of prostate cancer. Oncotarget 2018;9:2002-16. [PMID: 29416748 DOI: 10.18632/oncotarget.23111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
2 Robbins HL, Hague A. The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) 2015;6:188. [PMID: 26793165 DOI: 10.3389/fendo.2015.00188] [Cited by in Crossref: 38] [Cited by in F6Publishing: 49] [Article Influence: 6.3] [Reference Citation Analysis]
3 Jang S, Yu XM, Odorico S, Clark M, Jaskula-Sztul R, Schienebeck CM, Kupcho KR, Harrison AD, Winston-McPherson GN, Tang W, Chen H. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. Cancer Gene Ther 2015;22:410-6. [PMID: 26251030 DOI: 10.1038/cgt.2015.37] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
4 Liu J, Wang L, Zhang Y, Li S, Sun F, Wang G, Yang T, Wei D, Guo L, Xiao H. Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications. Oncol Lett 2019;17:3151-62. [PMID: 30867745 DOI: 10.3892/ol.2019.9951] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
5 Cui H, Cheng Y, He Y, Cheng W, Zhao W, Zhao H, Zhou FH, Wang L, Dong J, Cai S. The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑induced asthma mouse model. Mol Med Rep 2020;22:3723-34. [PMID: 33000187 DOI: 10.3892/mmr.2020.11450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Jang S, Yu XM, Montemayor-Garcia C, Ahmed K, Weinlander E, Lloyd RV, Dammalapati A, Marshall D, Prudent JR, Chen H. Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes. Oncotarget 2017;8:24457-68. [PMID: 28160550 DOI: 10.18632/oncotarget.14904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Aburjania Z, Whitt JD, Jang S, Nadkarni DH, Chen H, Rose JB, Velu SE, Jaskula-Sztul R. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules 2020;25:E4940. [PMID: 33114525 DOI: 10.3390/molecules25214940] [Reference Citation Analysis]
8 Jiao P, Zhou YS, Yang JX, Zhao YL, Liu QQ, Yuan C, Wang FZ. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem 2013;382:217-24. [PMID: 23797319 DOI: 10.1007/s11010-013-1737-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
9 Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M, Gamblin TC. Inhibition of the AKT pathway in cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int 2015;15:13. [PMID: 25674039 DOI: 10.1186/s12935-015-0161-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
10 Somnay Y, Lubner S, Gill H, Matsumura JB, Chen H. The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids. Cancer Gene Ther 2016;23:348-54. [PMID: 27632933 DOI: 10.1038/cgt.2016.39] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
11 Weinlander E, Somnay Y, Harrison AD, Wang C, Cheng YQ, Jaskula-Sztul R, Yu XM, Chen H. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth. J Surg Res 2014;190:191-7. [PMID: 24679699 DOI: 10.1016/j.jss.2014.02.042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
12 Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocr Connect 2018;7:R1-R25. [PMID: 29146887 DOI: 10.1530/EC-17-0286] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
13 Somnay YR, Dull BZ, Eide J, Jaskula-Sztul R, Chen H. Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids. Cancer Gene Ther 2015;22:496-505. [PMID: 26403073 DOI: 10.1038/cgt.2015.49] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]